Skip to main content
. 2011 Jul 11;108(30):12455–12460. doi: 10.1073/pnas.1104361108

Fig. 5.

Fig. 5.

p62/SQSTM1 is required for TSC2-null tumor development. (A) Immunoblot analysis of p62/SQSTM1 and tuberin (TSC2) in matched pairs of angiomyolipoma (T1–T3) and adjacent normal kidney (N1–N3). (B) Immunohistochemical analysis of p62/SQSTM1 accumulation in LAM nodules, which are positive for muscle actin. (Original magnification, 20× and 60×.) N, normal lung. L, LAM cells. (C) Immunoblot analysis of p62/SQSTM1 and LC3-II in Tsc2−/− MEFs stably infected with lentiviral control or p62/SQSTM1 shRNA. (D) Cell growth as assessed by the ATPlite cell viability assay. (E) Immunoblot analysis of phospho-p44/42 MAPK (Thr202/Try204) and phospho-IKKα/β (Ser176/180) in Tsc2−/− MEFs stably infected with lentiviral control or p62/SQSTM1 shRNA. (F) Kaplan–Meier plot of the percentage of tumor-free mice after inoculation with Tsc2−/− MEFs stably infected with lentiviral control or p62/SQSTM1 shRNA. *P < 0.05, Mantel–Cox log-rank test. (G) Immunoblot analysis of p62/SQSTM1 in xenograft tumors from F.